A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

NCT07223125 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced-stage Solid Tumors

Interventions

DRUG: JNJ-89862175

Sponsor

Janssen Research & Development, LLC